Advancing Care in ER+/HER2− Metastatic Breast Cancer

Explore the evidence behind vepdegestrant and what it means for treatment decisions and patient access in ER+/HER2− metastatic breast cancer.

Seth Wander, MD, PhD (Massachusetts General Hospital & Medicine, Harvard Medical School), and Douglas Braun, PharmD, CSP, CPh (NCODA), will discuss:

• The clinical relevance of ESR1 mutations and testing at disease progression.
• Vepdegestrant’s PROTAC mechanism and how it differs from other estrogen receptor–directed therapies.
• Efficacy, safety, and tolerability data, including considerations for patient selection and clinical use.
• The role of Oncology Optimized Limited Distribution (OOLD) in supporting access within medically integrated oncology practices.

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.